High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia Supplementary Materials
Supplementary Table S1: Patients’ characteristics in the validating group of CN-AML according to the RUNX1 expression Variable RUNX1high, n = 81 RUNX1low, n = 81 P Median age. y (range) 59 (7–81) 56 (20–83) 0.82 Median OS. d (range) 223 (3–1176) 416 (1–1176) 0.03 FAB subtype, no M0 2 3 1 M1 30 15 0.014 M2 18 27 0.16 M3 0 0 1 M4 22 20 0.86 M5 8 11 0.63 M6 1 5 0.21 61 20 < 0.001 High ERG, no 48 33 0.028 High BAALC, no 28 53 < 0.001 High LEF1, no 44 37 0.35 High MN1, no 54 27 < 0.001 High WT1, no 56 25 < 0.001 High DNMT3B, no 60 21 < 0.001 High TCF4, no 63 18 < 0.001 High ITPR2, no 58 23 < 0.001 High MAPKBP1, no High ERG, BAALC, LEF1, MN1,WT1, DNMT3B TCF4, ITPR2 and MAPKBP1 expression were defined as an expression level above the median of all samples, respectively.
www.impactjournals.com/oncotarget
1
Oncotarget
Supplementary Table S2: RUNX1-associated gene-expression profile using microarray in the testing group probes
